Difference between revisions of "Depression in Parkinson's disease"
| Line 1: | Line 1: | ||
'''Diagnosis''' | '''Diagnosis''' | ||
| − | * Be aware of significant overlap between depressive symptoms with PD | + | * Be aware of significant overlap between depressive symptoms with PD |
| + | ** psychomotor slowing, lack of facial expression, fatigue, and diminished attention are shared between depression and PD (Timmer et al, 2017) | ||
| + | ** alternatively, symptoms of dysphoria, irritability, pessimism regarding the future, feeling of inadequacy, and sense of guilt are more specific to depression in PD (Assogna et al, 2020) | ||
* Distinguish depression (high degree of subjective suffering) from apathy (low degree of subjective suffering) (Timmer et al, 2017) | * Distinguish depression (high degree of subjective suffering) from apathy (low degree of subjective suffering) (Timmer et al, 2017) | ||
* Distinguish psychotic features from depression (mood congruent) from psychotic features 2/2 dopaminergic treatment or cognitive decline (mood incongruent) (Timmer et al, 2017) | * Distinguish psychotic features from depression (mood congruent) from psychotic features 2/2 dopaminergic treatment or cognitive decline (mood incongruent) (Timmer et al, 2017) | ||
| Line 15: | Line 17: | ||
== References == | == References == | ||
| + | Assogna F, et al. Drug choices and advancements of managing deprssion in Parkinson's disease. Curr Neuropharmacol. v.18(4); 2020 Apr. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7327944/ | ||
| + | |||
Barone, P. et al. Pramipexole versus sertraline in the treatment of depression in Parkinson’s disease: A national multicenter parallel–group randomized study. J. Neurol. 253, 601–607 (2006). https://pubmed.ncbi.nlm.nih.gov/16607468/ | Barone, P. et al. Pramipexole versus sertraline in the treatment of depression in Parkinson’s disease: A national multicenter parallel–group randomized study. J. Neurol. 253, 601–607 (2006). https://pubmed.ncbi.nlm.nih.gov/16607468/ | ||
| − | Barone, | + | Barone P, et al. Pramipexole for the treatment of depressive symptoms in patients with Parkinson’s disease: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 9, 573–580 (2010). https://pubmed.ncbi.nlm.nih.gov/20452823/ |
Caillava-Santos, F., Margis, R. & Rieder, C. Wearing-off in Parkinson’s disease: neuropsychological differences between on and off periods. Neuropsychiatr. Dis. Treat. 1175 (2015) doi:10.2147/NDT.S77060. https://pubmed.ncbi.nlm.nih.gov/25999721/ | Caillava-Santos, F., Margis, R. & Rieder, C. Wearing-off in Parkinson’s disease: neuropsychological differences between on and off periods. Neuropsychiatr. Dis. Treat. 1175 (2015) doi:10.2147/NDT.S77060. https://pubmed.ncbi.nlm.nih.gov/25999721/ | ||
Timmer, M. H. M., van Beek, M. H. C. T., Bloem, B. R. & Esselink, R. A. J. What a neurologist should know about depression in Parkinson’s disease. Pract. Neurol. 17, 359–368 (2017). https://pubmed.ncbi.nlm.nih.gov/28739866/ | Timmer, M. H. M., van Beek, M. H. C. T., Bloem, B. R. & Esselink, R. A. J. What a neurologist should know about depression in Parkinson’s disease. Pract. Neurol. 17, 359–368 (2017). https://pubmed.ncbi.nlm.nih.gov/28739866/ | ||
Revision as of 08:27, 11 November 2021
Diagnosis
- Be aware of significant overlap between depressive symptoms with PD
- psychomotor slowing, lack of facial expression, fatigue, and diminished attention are shared between depression and PD (Timmer et al, 2017)
- alternatively, symptoms of dysphoria, irritability, pessimism regarding the future, feeling of inadequacy, and sense of guilt are more specific to depression in PD (Assogna et al, 2020)
- Distinguish depression (high degree of subjective suffering) from apathy (low degree of subjective suffering) (Timmer et al, 2017)
- Distinguish psychotic features from depression (mood congruent) from psychotic features 2/2 dopaminergic treatment or cognitive decline (mood incongruent) (Timmer et al, 2017)
- PD patients with depression seem more vulnerable to developing impulse control disorders 103 (see below)
Treatment
- Is depression related to motor fluctuations or undertreatment?
- In a study examining nonmotor symptoms related to on and off periods, patients presented higher depression and anxiety scores in the wearing-off periods, as well as worse semantic verbal fluency and executive function performance (Caillava-Santos, Margis, and Rieder, 2015)
- Optimize dopaminergic regimen; levodopa may have an antidepressant effect; other dopamine receptor agonists have shown antidepressant effect, such as pramipexole, which was statistically greater than placebo (Barone et al, 2010) and similar to sertraline antidepressant effect (Barone et al, 2006)
References
Assogna F, et al. Drug choices and advancements of managing deprssion in Parkinson's disease. Curr Neuropharmacol. v.18(4); 2020 Apr. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7327944/
Barone, P. et al. Pramipexole versus sertraline in the treatment of depression in Parkinson’s disease: A national multicenter parallel–group randomized study. J. Neurol. 253, 601–607 (2006). https://pubmed.ncbi.nlm.nih.gov/16607468/
Barone P, et al. Pramipexole for the treatment of depressive symptoms in patients with Parkinson’s disease: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 9, 573–580 (2010). https://pubmed.ncbi.nlm.nih.gov/20452823/
Caillava-Santos, F., Margis, R. & Rieder, C. Wearing-off in Parkinson’s disease: neuropsychological differences between on and off periods. Neuropsychiatr. Dis. Treat. 1175 (2015) doi:10.2147/NDT.S77060. https://pubmed.ncbi.nlm.nih.gov/25999721/
Timmer, M. H. M., van Beek, M. H. C. T., Bloem, B. R. & Esselink, R. A. J. What a neurologist should know about depression in Parkinson’s disease. Pract. Neurol. 17, 359–368 (2017). https://pubmed.ncbi.nlm.nih.gov/28739866/
